Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026GuruFocus · 1 day ago
/C O R R E C T I O N - AbbVie/GuruFocus · 6 days ago
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioGuruFocus · 6 days ago
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressGuruFocus · 6 days ago
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian CancerGuruFocus · Oct 3, 2026Procaps Group S.A., established in Luxembourg in 1977, functions as a global pharmaceutical enterprise dedicated to the creation, production, and distribution of a broad spectrum of pharmaceutical solutions. The company manufactures and markets branded prescription medications addressing diverse therapeutic needs, including women's health, pain management, dermatological conditions, digestive disorders, growth and development, cardiovascular care, vision health, central nervous system ailments, and respiratory issues. In addition to prescription drugs, Procaps supplies a suite of products for hospital use, encompassing antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics.